Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications
Effectiveness of islatravir post-exposure prophylaxis after intravenous challenge with simian immunodeficiency virus in rhesus macaques.
Journal: Journal of the International AIDS Society
Published: October 16, 2024
Y RNAs are conserved endogenous RIG-I ligands across RNA virus infection and are targeted by HIV-1.
Journal: iScience
Published: October 25, 2021
Introduction: long-acting antiretrovirals for the treatment and prevention of HIV-1 infection: the future is now.
Journal: Current opinion in HIV and AIDS
Published: November 13, 2019
Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1.
Journal: Current opinion in HIV and AIDS
Published: October 29, 2019
Drug Resistance Mutation Frequency of Single-Genome Amplification-Derived HIV-1 Polymerase Genomes in the Cerebrospinal Fluid and Plasma of HIV-1-Infected Individuals under Nonsuppressive Therapy.
Journal: Journal of virology
Published: October 28, 2019
Once-Weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques From Intrarectal Challenge With SHIV109CP3.
Journal: The Journal of infectious diseases
Published: February 21, 2019
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
Journal: HIV clinical trials
Published: November 18, 2018
Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial.
Journal: Frontiers in immunology
Published: October 24, 2018
4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor.
Journal: Current opinion in HIV and AIDS
Published: April 27, 2018
Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1.
Journal: Expert opinion on investigational drugs
Published: April 11, 2018
Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States.
Journal: AIDS and behavior
Published: January 01, 2018
Last Updated: 09/26/2026